Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Activation of PTK receptors in solid human tumors
- Human kinome
- Human tyrosine kinases
- Human PTK receptors (RTKs)
- The role of TKs in cancer
- Receptor tyrosine kinases altered in solid tumors
- Mechanism of activation of RTKs
- Ligand dependent activation of RTK (1)
- Ligand dependent activation of RTK (2)
- Ligand dependent activation of RTK (3)
- Ligand dependent activation of RTK (4)
- Pathological activation of RTKs
- Autocrine loop
- Autocrine loop in solid human tumors
- Pathological activation by autocrine loop (1)
- Pathological activation by autocrine loop (2)
- Pathological activation by autocrine loop (3)
- Pathological activation by autocrine loop (4)
- Pathological activation by autocrine loop (5)
- Pathological activation by autocrine loop (6)
- Autocrine loop in solid human tumors - DP
- Dermatofibrosarcoma protuberans DP
- Characterization of PD
- Gene fusion in DP
- PDGF break point are upstream exon 2
- Transforming the fusion gene
- Growth inhibitory effect of STI571
- In vivo effects of Gleevec on tumor growth
- Gene amplification
- Gene amplification - examples
- Pathological activation by gene amplification (1)
- Pathological activation by gene amplification (2)
- Pathological activation by gene amplification (3)
- Gene amplification - Her2
- Her2 expression in breast cancer
- Effect of histological grade on disease free survival
- Mutation
- Mutation - example
- Pathological activation by mutation (1)
- Pathological activation by mutation (2)
- Pathological activation by mutation (3)
- Pathological activation by mutation (4)
- Mutation - EGFR and Her2
- EGFR mutations in lung cancer
- Mutations in the TK domain
- Intragenic ERBB2 kinase mutations in tumors
- Pathological activation by mutation
- Mutation - Ret
- Pathological condition associated to Ret mutations
- Ret germline activating mutations
- Disulfide bond-mediated RET dimerization
- Dimerization and tyrosine phosphorylation of Ret
- Gene rearrangement
- Gene rearrangement - examples
- Pathological activation by gene rearrangement
- Gene rearrangement - TRK and Ret
- Ret and TRK oncogenes in PTC
- Inv (10) (q11.2q21)
- Ret and TRK thyroid oncogenes
- Genes activating Ret and TRK
- Ret and TRK oncoproteins display TK activity
- Ret and NTRK1 in human diseases
- Tyrosine kinase as therapeutic targets
- Gleevec as a paradigm of Rtk targeted therapy
- Gleevec, dermatofibrosarcoma P, PDGFR
- Gleevec, Gist, Kit: a case report
- Biochemical experiments
- DNA sequencing
- In vitro experiments
- Gefitinib, NSCLC, EGFR
- EGFR TK mutations
- Gefitinib, colorectal cancer, EGFR
- Genetic profile of metastatic colorectal cancer
- EGFR gene copy number and anti EGFR response
- A new paradogm
- High throughput sequencing
- A screen of the complete PK gene family
- Cancer genetics - conclusionj
Topics Covered
- The human kinome
- Role of tyrosine kinases in cancer
- Mechanisms of activation of RTKs in physiological and pathological conditions
- Autocrine Loop
- The dermatofibrosarcoma protuberans model
- Gene Amplification
- the breast cancer model
- Mutation
- The EGFR and lung cancer model
- The Ret and multiple endocrine type 2 syndrom model
- Gene rearrangment
- The RET and TRK in papillary thyroid carcinoma model
- Thyrosine Kinases and therapeutic targets
- The Gleevec paradigm
- The EGFR inhibitors a new paradigm
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Pierotti, M. (2007, October 1). Activation of PTK receptors in solid human tumors [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 7, 2024, from https://doi.org/10.69645/OXOV2356.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Marco Pierotti has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.